Reconsideration of severe hypoglycemic events in the treat-to-target trial

Diabetes Technology and Therapeutics

Volumn 11, Issue 8, 2009, Pages 477-479

  Dailey, George ^a   Strange, Poul ^b   Riddle, Matthew ^c  

^a SCRIPPS CLINIC   (United States)

^b Integrated Medical Development LLC   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIMEPIRIDE; GLIMEPIRIDE PLUS METFORMIN; GLIPIZIDE PLUS METFORMIN; GLUCAGON; GLUCOSE; INSULIN GLARGINE; ISOPHANE INSULIN; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; ARTICLE; CARBOHYDRATE INTAKE; DISEASE SEVERITY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, NPH; SULFONYLUREA COMPOUNDS;

EID: 70349436978     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2009.0022     Document Type: Article

References (1)

1. Riddle MC, Rosenstock J, Gerich J; the Insulin Glargine 4002 Study Investigators: The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.